BioXcel Therapeutics Azioni (NASDAQ: BTAI)

BioXcel Therapeutics (NASDAQ:BTAI) Azioni, Quote.MetaTitle.unusual-options

BioXcel Therapeutics

BioXcel Therapeutics, Inc. - Common Stock

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Comments

BioXcel Therapeutics Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO